Safety, Tolerability and Clinical Effects of a Rapid Dose Titration of Subcutaneous Treprostinil Therapy in Pulmonary Arterial Hypertension: A Prospective Multi-Centre Trial

Publisher： Karger

E-ISSN： 1423-0356|92|6|362-370

ISSN： 0025-7931

Source： Respiration, Vol.92, Iss.6, 2016-10, pp. : 362-370

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Use of subcutaneous treprostinil in pediatric pulmonary arterial hypertension—Bridge‐to‐transplant or long‐term treatment?

By  

PEDIATRIC TRANSPLANTATION, Vol. 22, Iss. 2, 2018-03 ,pp. : n/a-n/a

John Wiley & Sons Inc

Access to resources Recommend Favorite

Cost-minimization analysis of treprostinil vs. epoprostenol as an alternate to oral therapy non-responders for the treatment of pulmonary arterial hypertension

By Narine L.   Hague L. K.   Walker J. H.   Vicente C.   Schilz R.   Desjardins O.   Einarson T. R.   Iskedjian M.  

Current Medical Research and Opinion, Vol. 21, Iss. 12, 2005-12 ,pp. : 2007-2016

Informa Healthcare

Access to resources Recommend Favorite

bloodstream infection in a pediatric patient with pulmonary arterial hypertension receiving intravenous treprostinil therapy

By Wen A.   Weiss I.   Kelly R.  

Infection, Vol. 41, Iss. 3, 2013-06 ,pp. : 719-722

Springer Publishing Company

Access to resources Recommend Favorite

Efficacy and Safety of Long-Term Imatinib Therapy for Pulmonary Arterial Hypertension

By  

Respiration, Vol. 89, Iss. 6, 2015-06 ,pp. : 515-524

Karger

Access to resources Recommend Favorite

Combination Therapy in Pulmonary Arterial Hypertension

By  

Cardiology, Vol. 123, Iss. 1, 2012-09 ,pp. : 41-41

Karger

Access to resources Recommend Favorite